While microneedle patches and other advanced delivery technologies are under investigation in preclinical and early clinical studies, patients should be aware that any information about "wearing" GLP-1 patches currently refers to investigational products not yet available for prescription use
Anna Bartter is a freelance journalist who writes about health, fitness and women's lifestyle for publications including Women's Health, Stylist, The iPaper, Metro and Psychologies, among others
Acknowledgements This work was supported by the National Institutes of Health (R01 GM056414, to S.H.G.)
However, the FDA There is an intense race among pharmaceutical companies to enter the GLP-1 medication market, especially in countries outside the United States, where patents are expiring
It was FDA-approved for obesity treatment in 2021
Enhanced metabolic function: Retatrutides unique activation of glucagon receptors adds to its appeal by boosting energy expenditure and metabolic rate, contributing to overall metabolic health
